SCHEMBL6238822

SCHEMBL6238822

COC(=O)C1(C)NCCc2c1[nH]c1ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
LMNA P02545 2/20 0.49
OPRM1 P35372 3/20 0.46
OPRL1 P41146 2/20 0.46
OGFRL1 Q5TC84 2/20 0.46
TRPA1 O75762 3/20 0.45
TRPV1 Q8NER1 2/20 0.45
MEN1 O00255 2/20 0.44
BCHE P06276 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
KDM4E B2RXH2 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
PAX8 Q06710 1/20 0.43
OPRD1 P41143 3/20 0.43
OPRK1 P41145 2/20 0.43
CHRNB4 P30926 1/20 0.43
CHRNA3 P32297 1/20 0.43
MAPT P10636 2/20 0.41
CDK8 P49336 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9685713 0.86 KMT2A (0.62) KMT2ALMNAOPRM1OPRL1OGFRL1
SCHEMBL9480993 0.85 LMNA (0.52) KMT2ALMNAOPRM1OPRL1OGFRL1
SCHEMBL11318061 0.85 LMNA (0.49) KMT2ALMNAOPRM1OPRL1OGFRL1
SCHEMBL2706382 0.84 MAPKAPK2 (0.44) OPRM1OGFRL1
SCHEMBL10617106 0.83 KMT2A (0.51) KMT2ALMNAOPRM1OPRL1OGFRL1
SCHEMBL2705403 0.83 CFTR (0.42) LMNAOPRM1OGFRL1MAPTALDH1A1
SCHEMBL2780429 0.83 MAPKAPK2 (0.45) KMT2ALMNAMEN1MAPT
SCHEMBL2706845 0.83 MAPKAPK2 (0.52) LMNATRPA1TRPV1KDM4EMAPT
SCHEMBL11458021 0.83 KMT2A (0.54) KMT2ALMNATRPA1TRPV1MEN1
SCHEMBL9685278 0.83 KMT2A (0.40) KMT2AOPRM1OGFRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0891187-B1 USE OF DERIVATIVES OF TETRAHYDRO-BETA-CARBOLINES AS ANTIMETASTATIC AGENTS HOFFMANN LA ROCHE (CH) 2002-01-30 EP claimed
US-6069150-A METALLOPROTRINASE INHIBITOR F. HOFFMAN-LA ROCHE AG (CH) 2000-05-30 US claimed
EP-0273321-B1 7-BROMO-BETA-CARBOLINE COMPOUND AND METHOD FOR PRODUCING SAME Kawaken Fine Chemicals Co., Ltd. (JP) 1992-04-22 EP claimed
US-4894457-A BROMINATION, HYDROLYSIS KAWAKEN FINE CHEMICALS CO., LTD. (JP) 1990-01-16 US claimed
EP-0273321-A1 7-Bromo-beta-carboline compound and method for producing same Kawaken Fine Chemicals Co., Ltd. (JP) 1988-07-06 EP claimed
US-20250324119-A1 SYSTEMS AND METHODS FOR ADAPTIVE ADJUSTMENT OF ADVERTISEMENT BOUNDARIES IN MEDIA NIELSEN CO US LLC (US) 2025-10-16 US disclosed
US-12363363-B2 Systems and methods for adaptive adjustment of advertisement boundaries in media THE NIELSEN COMPANY (US), LLC (US) 2025-07-15 US disclosed
US-20240040173-A1 SYSTEMS AND METHODS FOR ADAPTIVE ADJUSTMENT OF ADVERTISEMENT BOUNDARIES IN MEDIA THE NIELSEN COMPANY (US), LLC (US) 2024-02-01 US disclosed
US-20050137220-A1 Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors PHARMACIA CORPORATION (US) 2005-06-23 US disclosed
WO-2005009370-A2 BETA-CARBOLINE COMPOUNDS AND ANALOGUES THEREOF AND THEIR USE AS MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS PHARMACIA CORPORATION (US) 2005-02-03 WO disclosed
EP-0891187-B1 USE OF DERIVATIVES OF TETRAHYDRO-BETA-CARBOLINES AS ANTIMETASTATIC AGENTS HOFFMANN LA ROCHE (CH) 2002-01-30 EP disclosed
US-6069150-A METALLOPROTRINASE INHIBITOR F. HOFFMAN-LA ROCHE AG (CH) 2000-05-30 US disclosed
EP-0273321-B1 7-BROMO-BETA-CARBOLINE COMPOUND AND METHOD FOR PRODUCING SAME Kawaken Fine Chemicals Co., Ltd. (JP) 1992-04-22 EP disclosed
US-4894457-A BROMINATION, HYDROLYSIS KAWAKEN FINE CHEMICALS CO., LTD. (JP) 1990-01-16 US disclosed
EP-0273321-A1 7-Bromo-beta-carboline compound and method for producing same Kawaken Fine Chemicals Co., Ltd. (JP) 1988-07-06 EP disclosed
US-4336256-A TREATMENT OF ANOXIA, DEPRESSION AND IN PSYCHOTROPIC THERAPY SYNTHELABO (FR) 1982-06-22 US disclosed
US-4272539-A ANOXIA, ANTIDEPRESSANTS SYNTHELABO (FR) 1981-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137220-A1 Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors MAPKAPK2, MAP4K2, MAP3K2 KMT2A 500/4885LMNA 3942/4885OPRM1 2196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.